» Articles » PMID: 29481536

Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents

Overview
Journal Health Phys
Date 2018 Feb 27
PMID 29481536
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

There is a growing need to estimate the absorbed dose to small animals from preclinical investigations involving diagnostic and therapeutic radiopharmaceuticals. This paper introduces a Monte Carlo-based dosimetry platform called RAPID, which is capable of calculating murine-specific three-dimensional (3D) dose distributions. A comparison is performed between absorbed doses calculated with RAPID and absorbed doses calculated in a commonly used reference mouse phantom called MOBY. Four test mice containing different xenografts underwent serial PET/CT imaging using a novel diagnostic therapy (theranostic) agent NM404, which can be labeled with I for imaging or I for therapy. Using the PET/CT data, 3D dose distributions from I-NM404 were calculated in the mice using RAPID. Mean organ doses in these four test mice were compared to mean organ doses derived by using two previously published I S-values datasets in MOBY. In addition, mean tumor doses calculated in RAPID were compared to mean organ doses derived from unit density spheres. Large differences were identified between mean organ doses calculated in the test mice using RAPID and those derived in the MOBY phantom. Mean absorbed dose percent errors in organs ranged between 0.3% and 333%. Overall, mass scaling improved agreement between MOBY phantom calculations and RAPID, where percent errors were all less than 26%, with the exception of the lung in which percent errors reached values of 48%. Percent errors in mean tumor doses in the test mice and unit density spheres were less pronounced but still ranged between 8% and 23%. This work demonstrates the limitations of using pre-computed S-values in computational phantoms to predict organ doses in small animals from theranostic procedures. RAPID can generate accurate 3D dose distributions in small animals and in turn offer much greater insight on the ability of a given theranostic agent to image and treat diseases.

Citing Articles

Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors.

Muralidhar A, Hernandez R, Morris Z, Rojas H, Idrissou M, Weichert J J Immunother Cancer. 2024; 12(4).

PMID: 38663936 PMC: 11043705. DOI: 10.1136/jitc-2023-008760.


Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody.

Allen K, Kwon O, Hutcheson M, Grudzinski J, Cain S, Cruz F Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513891 PMC: 10384855. DOI: 10.3390/ph16070979.


Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.

Marsh I, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam D Cancer Biother Radiopharm. 2023; 38(7):458-467.

PMID: 37022739 PMC: 10516227. DOI: 10.1089/cbr.2022.0084.


Antitumor efficacy of Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.

Potluri H, Ferreira C, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle J J Immunother Cancer. 2022; 10(8).

PMID: 36002185 PMC: 9413196. DOI: 10.1136/jitc-2022-005060.


Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules.

Cicone F, Viertl D, Denoel T, Stabin M, Prior J, Gnesin S EJNMMI Res. 2022; 12(1):21.

PMID: 35403982 PMC: 9001797. DOI: 10.1186/s13550-022-00893-z.


References
1.
Hindorf C, Ljungberg M, Strand S . Evaluation of parameters influencing S values in mouse dosimetry. J Nucl Med. 2004; 45(11):1960-5. View

2.
Flynn A, Green A, Pedley R, Boxer G, Boden R, Begent R . A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor. Radiat Res. 2001; 156(1):28-35. DOI: 10.1667/0033-7587(2001)156[0028:ammfct]2.0.co;2. View

3.
Weichert J, Clark P, Kandela I, Vaccaro A, Clarke W, Longino M . Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014; 6(240):240ra75. PMC: 4336181. DOI: 10.1126/scitranslmed.3007646. View

4.
Hui T, Fisher D, Kuhn J, Williams L, Nourigat C, Badger C . A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer. 1994; 73(3 Suppl):951-7. DOI: 10.1002/1097-0142(19940201)73:3+<951::aid-cncr2820731330>3.0.co;2-1. View

5.
Xie T, Zaidi H . Monte Carlo-based evaluation of S-values in mouse models for positron-emitting radionuclides. Phys Med Biol. 2012; 58(1):169-82. DOI: 10.1088/0031-9155/58/1/169. View